Skip to main content

Beneficial ownership — 13D / 13G

87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Randall Moreadith SER Serina Therapeutics, Inc. 13D 6.8% 2y
Socoservin Overseas SPF S.a.r.l. GPRK GeoPark Ltd 13G/A 5.22% 2y
Sumitomo Chemical Co., Ltd. ROIV Roivant Sciences Ltd. 13G/A 0% 2y
New Enterprise Associates 14, L.P. ADAPY Adaptimmune Therapeutics PLC 13D/A 6.7% 2y
Charles W. Ergen ECHO EchoStar CORP 13D/A 54% 2y
BROWNING WEST LP GIL Gildan Activewear Inc. 13D/A 5% 2y
Brookstone Capital Management AAPR Innovator ETFs Trust 13G 13.41% 2y
Brookstone Capital Management AAPR Innovator ETFs Trust 13G/A 3.01% 2y
General Electric Co GEHC GE HealthCare Technologies Inc. 13G/A 6.7% 2y
Brookstone Capital Management AAPR Innovator ETFs Trust 13G 17.55% 2y
Brookstone Capital Management AAPR Innovator ETFs Trust 13G/A 2.12% 2y
David J. Lubar HNRG Hallador Energy Co 13D/A 15.09% 2y
Newhouse Broadcasting Corporation WBD Warner Bros. Discovery, Inc. 13D/A 8.12% 2y
Silver Lake West HoldCo, L.P. EDR Endeavor Group Holdings, Inc. 13D/A 45.4% 2y
Maurice Marciano GES Guess, Inc. 13D/A 21.5% 2y
Paul Marciano GES Guess, Inc. 13D/A 37.2% 2y
AKIN THOMAS B MHLA Maiden Holdings, Ltd. 13G/A 7.2% 2y
AKIN THOMAS B HIPO Hippo Holdings Inc. 13G 2.2% 2y
BML Investment Partners, L.P. TIL Instil Bio, Inc. 13G 5.3% 2y
John J. Bello REED Reed's, Inc. 13D/A 15.2% 2y
KVC Sponsor LLC KVACF Keen Vision Acquisition Corp. 13G 22.8% 2y
Maximilian Thyssen SFRX Seafarer Exploration Corp 13G/A 7.48% 2y
KOONCE CALVIN SCOTT VSEC Vse Corp 13D/A 11.9% 2y
Vintage Investments 5 L.P. CTV Innovid Corp. 13G/A 3.3% 2y
Logos Global Management LP NXTC NextCure, Inc. 13G 7.2% 2y
EquityLine Alternate Assets GP Inc. MBAI MBody AI Ltd. 13D 13% 2y
H.I.G. Growth – AdTheorent, LLC ADTH AdTheorent Holding Company, Inc. Common Stock 13D/A 37.5% 2y
Fairmount Funds Management LLC DNTH Dianthus Therapeutics, Inc. 13D/A 9.99% 2y
STG III, L.P. TBLA Taboola.com Ltd. 13G/A 2.5% 2y
Simeon A. Thibeaux RRBI Red River Bancshares Inc 13G/A 15.1% 2y
Ryan Michael Pratt GUER Guerrilla RF, Inc. 13D/A 9.88% 2y
Saba Capital Management, L.P. SABA Saba Capital Income & Opportunities Fund II 13D/A 12.61% 2y
Salem Investment Partners V, Limited Partnership ( ) GUER Guerrilla RF, Inc. 13D/A 17.2% 2y
BAKER BROS. ADVISORS LP KYMR Kymera Therapeutics, Inc. 13D 9.8% 2y
AMB Investments LLC GUER Guerrilla RF, Inc. 13D/A 14.12% 2y
Comcast Ventures, LP ZPTA Zapata Quantum, Inc. 13G 8.7% 2y
TAKEDA PHARMACEUTICAL CO LTD PHAT Phathom Pharmaceuticals, Inc. 13D/A 5.4% 2y
Fairmount Funds Management LLC APGE Apogee Therapeutics, Inc. 13D/A 9.99% 2y
Fairmount Funds Management LLC VRDN Viridian Therapeutics, Inc.DE 13D/A 18.64% 2y
Fairmount Funds Management LLC COGT Cogent Biosciences, Inc. 13D/A 9.9% 2y
Avram Glazer Irrevocable Exempt Trust VATE INNOVATE Corp. 13D/A 29.1% 2y
TCG Crossover GP I, LLC KALV KalVista Pharmaceuticals, Inc. 13D/A 3.2% 2y
Runa Capital Opportunity I (GP) MRDB MariaDB plc 13D/A 8.7% 2y
Divisadero Street Capital Management, LP STIM Neuronetics, Inc. 13G 5.2% 2y
Lynx1 Capital Management LP IBIO iBio, Inc. 13G 9.99% 2y
TRUMP DONALD J DJT Trump Media & Technology Group Corp. 13D 57.6% 2y
L1 Capital Global Opportunities Master Fund, Ltd. SINT Sintx Technologies, Inc. 13G 8.8% 2y
Atlas Venture Fund X, L.P. QTTB Q32 Bio Inc. 13D 7.2% 2y
Stavros G. Vizirgianakis APYX Apyx Medical Corp 13D 5.04% 2y
Venrock Healthcare Capital Partners III, L.P. AQST Aquestive Therapeutics, Inc. 13G 6.5% 2y